- Home
- GILD
GILD
Gilead Sciences Inc.
as 12-19-2024 4:00pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 113.0B | IPO Year: | 1992 |
| Target Price: | $96.71 | AVG Volume (30 days): | 6.4M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.10 | EPS Growth: | -97.92 |
| 52 Week Low/High: | $62.07 - $98.90 | Next Earning Date: | 02-11-2025 |
| Revenue: | $28,299,000,000 | Revenue Growth: | 3.31% |
| Revenue Growth (this year): | 6.54% | Revenue Growth (next year): | -0.13% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | GILD | Chief Financial Officer | Nov 29 '24 | Sell | $92.76 | 248,645 | $23,065,270.54 | 266,849 | |
| Parsey Merdad | GILD | Chief Medical Officer | Nov 27 '24 | Sell | $91.88 | 164,211 | $15,094,013.40 | 80,801 | |
| Bluestone Jeffrey | GILD | Director | Nov 26 '24 | Sell | $91.39 | 6,788 | $620,356.00 | 8,920 | |
| Parsey Merdad | GILD | Chief Medical Officer | Nov 6 '24 | Sell | $91.50 | 25,590 | $2,341,485.00 | 80,801 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Nov 6 '24 | Sell | $91.28 | 5,000 | $456,400.00 | 73,127 | |
| Parsey Merdad | GILD | Chief Medical Officer | Oct 1 '24 | Sell | $83.83 | 2,000 | $167,660.00 | 80,801 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Zacks
14 hours ago
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
MT Newswires
a day ago
Assembly Biosciences Says It Will Receive $30.1 Million Funding From Gilead Sciences
Zacks
2 days ago
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Zacks
2 days ago
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
TipRanks
2 days ago
Gilead, Terray Therapeutics announce research collaboration
Pharmaceutical Technology
2 days ago
Gilead and Terray link to develop small-molecule therapies
MT Newswires
3 days ago
Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer
Business Wire
3 days ago
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.